Received Jul 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Throat reaction not anaphylactic; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of pharyngeal disorder in a patient who received Men ABCWY NVS (Penmenvy) suspension for injection in pre-filled syringe for prophylaxis. Co-suspect products included COVID-19 vaccine for prophylaxis. On an unknown date, the patient received Penmenvy and COVID-19 vaccine. On an unknown date, an unknown time after receiving Penmenvy, the patient experienced pharyngeal disorder (Verbatim: Throat reaction not anaphylactic). The patient was treated with acrivastine (Benadryl). The outcome of the pharyngeal disorder was resolved. It was unknown if the reporter considered the pharyngeal disorder to be related to Penmenvy and Penmenvy Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-JUL-2026 The patient experienced a throat reaction, not anaphylactic. Benadryl was administered, and symptoms resolved. The reporter was not sure if it was from Penmenvy or the coadministered Covid vaccine. The batch number was not provided and a request for this information has been made.